Efforts to improve access to MS treatments continue
The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).
The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS
Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US
Professor Alan Thompson highlights some of 2016’s research discoveries in MS